JPH08503615A - 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 - Google Patents
生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現Info
- Publication number
- JPH08503615A JPH08503615A JP6513423A JP51342394A JPH08503615A JP H08503615 A JPH08503615 A JP H08503615A JP 6513423 A JP6513423 A JP 6513423A JP 51342394 A JP51342394 A JP 51342394A JP H08503615 A JPH08503615 A JP H08503615A
- Authority
- JP
- Japan
- Prior art keywords
- gal
- enzyme
- cells
- protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)哺乳動物細胞がペプチドをシアリル化する能力を有するように、β- ガラクトシドα 2,6- シアリルトランスフェラーゼを発現するβ- ガラクトシド α 2,6- シアリルトランスフェラーゼ遺伝子で形質転換されており、さらに遺伝 子発現を調節するヌクレオチド配列に機能しうる状態で結合されたヒトα- ガラ クトシダーゼAをコードする、染色体に組み込まれた異種ヌクレオチド配列およ び同じまたは異なる調節配列によって制御される選択マーカーを含んでいる形質 転換哺乳動物細胞を培養し、こうしてα- ガラクトシダーゼAヌクレオチド配列 を安定して過剰に発現させ、そしてα- ガラクトシダーゼA酵素の酵素的に活性 なシアリル化グリコフォームを該哺乳動物細胞から分泌させ、そして (b)該哺乳動物細胞培地から酵素的に活性なα- ガラクトシダーゼA酵素を 単離する、 ことを含む、ヒトα- ガラクトシダーゼAの産生方法。 2.α- ガラクトシダーゼAをコードする前記のヌクレオチド配列が図1A−1 Cに示したヌクレオチド番号1から1299までの 配列を含むものである、請求項1に記載の方法。 3.α- ガラクトシダーゼAをコードする前記のヌクレオチド配列が図1A−1 Cに示したヌクレオチド番号91から1299までの配列を含むものである、請 求項1に記載の方法。 4.遺伝子発現を調節する前記のヌクレオチド配列がウイルスのプロモーターを 含むものである、請求項1に記載の方法。 5.遺伝子発現を調節する前記のヌクレオチド配列が誘導プロモー ターを含むものである、請求項1に記載の方法。 6.選択物質の存在下で、染色体に組み込まれた前記のヌクレオチド配列が増幅 される、請求項1に記載の方法。 7.選択マーカーがジヒドロ葉酸レダクターゼである、請求項1に記載の方法。 8.選択マーカーがジヒドロ葉酸レダクターゼであり、選択物質がメトトレキセ ートである、請求項6に記載の方法。 9.哺乳動物細胞がチャイニーズ・ハムスター卵巣細胞系である、請求項1に記 載の方法。 10.(a)遺伝子発現を調節するヌクレオチド配列に機能しうる状態で結合され た分泌タンパク質をコードするヌクレオチド配列を含んでいる形質転換哺乳動物 細胞を培養し、こうして該ヌクレオチド配列を安定して発現させかつ該タンパク 質を安定して発現させ、そして該形質転換哺乳動物細胞から該タンパク質を安定 して産生させて該哺乳動物細胞培地へ分泌される凝集物を形成させ、そして (b)該哺乳動物細胞培地から該タンパク質を単離する、 ことを含む、分泌タンパク質の産生方法。 11.前記のタンパク質が小胞体- 標的化、ゴルジ体- 標的化または膜- 標的化タ ンパク質である、請求項10に記載の方法。 12.前記のタンパク質がリソソームタンパク質である、請求項10に記載の方法。 13.前記のタンパク質が生物学的に活性なα- ガラクトシダーゼAである、請求 項10に記載の方法。 14.前記のタンパク質が生物学的に活性なα- N- アセチルガラク トサミニダーゼである、請求項10に記載の方法。 15.前記のタンパク質が酸スフィンゴミエリナーゼである、請求項10に記載の方 法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US983,451 | 1992-11-30 | ||
US07/983,451 US5401650A (en) | 1990-10-24 | 1992-11-30 | Cloning and expression of biologically active α-galactosidase A |
PCT/US1993/011539 WO1994012628A1 (en) | 1992-11-30 | 1993-11-30 | Cloning and expression of biologically active alpha-galactosidase a |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003401467A Division JP3598302B2 (ja) | 1992-11-30 | 2003-12-01 | 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08503615A true JPH08503615A (ja) | 1996-04-23 |
JP4005629B2 JP4005629B2 (ja) | 2007-11-07 |
Family
ID=25529958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51342394A Expired - Lifetime JP4005629B2 (ja) | 1992-11-30 | 1993-11-30 | 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 |
JP2003401467A Expired - Lifetime JP3598302B2 (ja) | 1992-11-30 | 2003-12-01 | 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003401467A Expired - Lifetime JP3598302B2 (ja) | 1992-11-30 | 2003-12-01 | 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 |
Country Status (14)
Country | Link |
---|---|
US (2) | US5401650A (ja) |
EP (4) | EP0670896B2 (ja) |
JP (2) | JP4005629B2 (ja) |
AT (2) | ATE213020T1 (ja) |
AU (1) | AU691795B2 (ja) |
CA (1) | CA2150555C (ja) |
DE (3) | DE69334327D1 (ja) |
DK (3) | DK0670896T3 (ja) |
ES (3) | ES2431293T3 (ja) |
IL (4) | IL220131A0 (ja) |
LU (2) | LU91703I2 (ja) |
PT (3) | PT2210947E (ja) |
SE (1) | SE2210947T5 (ja) |
WO (1) | WO1994012628A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122354B2 (en) | 1996-09-13 | 2006-10-17 | Transkaryotic Therapies, Inc. | Nucleic acid encoding a chimeric polypeptide |
JP2009060918A (ja) * | 1996-09-13 | 2009-03-26 | Transkaryotic Therapies Inc | α−ガラクトシダーゼA欠損症の治療 |
US7833742B2 (en) | 2002-04-25 | 2010-11-16 | Shire Human Genetic Therapies, Inc. | Treatment of α-galactosidase A deficiency |
JP2011037867A (ja) * | 1999-03-11 | 2011-02-24 | Transkaryotic Therapies Inc | α−ガラクトシダーゼA欠乏症の治療 |
JP2011184445A (ja) * | 2003-04-27 | 2011-09-22 | Protalix Ltd | 植物培養における高マンノースタンパク質の製造 |
JP2013520986A (ja) * | 2010-03-02 | 2013-06-10 | プロタリクス リミテッド | 安定化α−ガラクトシダーゼおよびその使用 |
JPWO2011108451A1 (ja) * | 2010-03-01 | 2013-06-27 | 日本ケミカルリサーチ株式会社 | 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法 |
US8741620B2 (en) | 2003-04-27 | 2014-06-03 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
JP2016530893A (ja) * | 2013-09-16 | 2016-10-06 | ジェンザイム・コーポレーション | 細胞培養物を処理する方法およびシステム |
US10364413B2 (en) | 2007-05-07 | 2019-07-30 | Protalix Ltd. | Large scale disposable bioreactor |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US20040064855A1 (en) * | 1988-02-26 | 2004-04-01 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US5179023A (en) * | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
WO1994023070A1 (en) * | 1993-03-26 | 1994-10-13 | New York Blood Center, Inc. | RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME |
AU2012227349B2 (en) * | 1996-09-13 | 2015-12-24 | Shire Human Genetic Therapies, Inc. | Therapy for alpha-galactosidase A deficiency |
US6455037B1 (en) * | 1996-11-01 | 2002-09-24 | Mount Sinai School Of Medicine Of The City University Of New York | Cells expressing an αgala nucleic acid and methods of xenotransplantation |
US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
EP1658857A1 (en) * | 1997-10-29 | 2006-05-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
IL135578A0 (en) * | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
AU776393B2 (en) * | 1998-12-23 | 2004-09-09 | Regeneron Pharmaceuticals, Inc. | Method of enhancing the biological activity of ligands |
AU2012241170B2 (en) * | 1999-03-11 | 2016-07-28 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
AU2016250357B2 (en) * | 1999-03-11 | 2018-11-01 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
US6642038B1 (en) * | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
CN1312383A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人alpha-半乳糖苷酶A-11和编码这种多肽的多核苷酸 |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
DE60224816T2 (de) * | 2001-04-30 | 2009-01-22 | ZyStor Therapeutics, Inc., Milwaukee | Subzelluläres targeting von therapeutischen proteinen |
JP4742191B2 (ja) * | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
US7767415B2 (en) | 2001-09-25 | 2010-08-03 | Velico Medical, Inc. | Compositions and methods for modifying blood cell carbohydrates |
NZ532027A (en) | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
CN105131104B (zh) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | 肽的重构和糖缀合 |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US6905856B2 (en) | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US20030124652A1 (en) * | 2001-12-21 | 2003-07-03 | Novazyme Pharmaceuticals, Inc. | Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells |
US6800472B2 (en) * | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
WO2003086452A2 (en) * | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
CA2814767C (en) | 2003-01-31 | 2016-03-15 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
EP1682504B1 (en) * | 2003-11-12 | 2012-12-26 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
EP1716232B9 (en) * | 2004-02-10 | 2010-10-13 | ZyStor Therapeutics , Inc. | Acid alpha-glucosidase and fragments thereof |
WO2006007560A2 (en) * | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
EP1793865A4 (en) * | 2004-08-05 | 2009-05-13 | Baylor Res Inst | GENETIC OR DRUG DELIVERY SYSTEM |
KR20080025373A (ko) | 2005-05-17 | 2008-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법 |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2007058381A1 (ja) | 2005-11-18 | 2007-05-24 | Tokyo Metropolitan Organization For Medical Research | 基質特異性を変換した新規高機能酵素 |
DK1986612T3 (da) | 2006-02-07 | 2012-10-29 | Shire Human Genetic Therapies | Stabiliserede proteinsammensætninger med en fri thioldel |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
EP2815768A3 (en) * | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
JP2010509344A (ja) * | 2006-11-13 | 2010-03-25 | ザイストール セラピューティクス, インコーポレイテッド | ポンペ病を治療するための方法 |
AU2008290217B2 (en) * | 2007-08-20 | 2013-09-05 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
SI3470077T1 (sl) * | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
CN102037356A (zh) | 2008-04-22 | 2011-04-27 | 洛克菲勒大学 | 鉴定抗炎化合物的方法 |
EP3778652A1 (en) | 2008-05-07 | 2021-02-17 | BioMarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
US8592555B2 (en) * | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
NZ591544A (en) * | 2008-09-30 | 2013-01-25 | Abbott Lab | Improved method of rna display |
SG195555A1 (en) * | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
US8785168B2 (en) | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
RU2733466C2 (ru) | 2009-07-28 | 2020-10-01 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
US20120328589A1 (en) | 2010-03-02 | 2012-12-27 | Ilya Ruderfer | Glucocerebrosidase multimers and uses thereof |
WO2012012461A2 (en) | 2010-07-19 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
US8679478B2 (en) | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
CN103391784A (zh) | 2010-10-15 | 2013-11-13 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
HUE045869T2 (hu) | 2010-11-02 | 2020-01-28 | Univ Columbia | Módszerek hajhullásos rendellenességek kezelésére |
SI3272861T1 (sl) | 2011-01-20 | 2020-06-30 | Protalix Ltd. | Alfa-galaktozidazni sestavki |
SG186552A1 (en) | 2011-06-08 | 2013-01-30 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
JP6230160B2 (ja) | 2012-03-02 | 2017-11-15 | シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド | Iii型ゴーシェ病を治療するための組成物および方法 |
JP6236406B2 (ja) | 2012-03-07 | 2017-11-22 | アミカス セラピューティックス インコーポレイテッド | ポンペ病の処置のための高濃度α−グルコシダーゼ組成物 |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
PL2830662T3 (pl) | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
EP2854910B1 (en) | 2012-06-01 | 2020-04-15 | Icahn School of Medicine at Mount Sinai | Ceramide levels in the treatment and prevention of infections |
WO2014016873A1 (en) | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
JP6226435B2 (ja) * | 2012-07-26 | 2017-11-08 | Jcrファーマ株式会社 | 組換えヒトα−ガラクトシダーゼAの製造方法 |
ES2739811T3 (es) | 2013-03-14 | 2020-02-04 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas |
ES2804594T3 (es) * | 2013-03-15 | 2021-02-08 | Amicus Therapeutics Inc | Reticuladores químicos |
TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
PT3201320T (pt) | 2014-09-30 | 2024-01-12 | Amicus Therapeutics Inc | Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados |
WO2016116966A1 (en) * | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
EP3347486A4 (en) | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE |
WO2017049157A1 (en) | 2015-09-18 | 2017-03-23 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
KR102343162B1 (ko) | 2016-03-30 | 2021-12-23 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
US11154591B2 (en) | 2016-10-14 | 2021-10-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
RU2698460C1 (ru) * | 2019-03-28 | 2019-08-27 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae |
US20220331408A1 (en) | 2019-07-09 | 2022-10-20 | Genethon | Treatment of glycogen storage disease (gsd) |
CN112795583A (zh) * | 2020-11-16 | 2021-05-14 | 上海大学 | 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法 |
AU2022261885A1 (en) * | 2021-04-20 | 2023-11-09 | Walking Fish Therapeutics, Inc. | Engineering b cell-based protein factories to treat serious diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH585793A5 (ja) * | 1974-02-01 | 1977-03-15 | Nestle Sa | |
JPS5322158B2 (ja) * | 1974-05-02 | 1978-07-06 | ||
IT1130242B (it) * | 1980-02-01 | 1986-06-11 | Anic Spa | Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
WO1990011353A1 (en) * | 1989-03-24 | 1990-10-04 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
US5032519A (en) * | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
DE4028800A1 (de) * | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
US5382524A (en) * | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
-
1992
- 1992-11-30 US US07/983,451 patent/US5401650A/en not_active Expired - Lifetime
-
1993
- 1993-11-30 EP EP94902448A patent/EP0670896B2/en not_active Expired - Lifetime
- 1993-11-30 EP EP00200454A patent/EP1020528A3/en not_active Ceased
- 1993-11-30 ES ES10157183T patent/ES2431293T3/es not_active Expired - Lifetime
- 1993-11-30 IL IL220131A patent/IL220131A0/en unknown
- 1993-11-30 ES ES94902448T patent/ES2168101T5/es not_active Expired - Lifetime
- 1993-11-30 IL IL200005A patent/IL200005A/en not_active IP Right Cessation
- 1993-11-30 JP JP51342394A patent/JP4005629B2/ja not_active Expired - Lifetime
- 1993-11-30 IL IL220132A patent/IL220132A0/en unknown
- 1993-11-30 AT AT94902448T patent/ATE213020T1/de not_active IP Right Cessation
- 1993-11-30 DK DK94902448T patent/DK0670896T3/da active
- 1993-11-30 DK DK07022356.5T patent/DK1942189T3/da active
- 1993-11-30 AU AU56817/94A patent/AU691795B2/en not_active Expired
- 1993-11-30 DE DE69334327T patent/DE69334327D1/de not_active Expired - Lifetime
- 1993-11-30 DE DE69331550T patent/DE69331550T3/de not_active Expired - Lifetime
- 1993-11-30 DE DE122010000028C patent/DE122010000028I1/de active Pending
- 1993-11-30 PT PT101571834T patent/PT2210947E/pt unknown
- 1993-11-30 SE SE10157183T patent/SE2210947T5/xx unknown
- 1993-11-30 IL IL107814A patent/IL107814A/en active Protection Beyond IP Right Term
- 1993-11-30 ES ES07022356T patent/ES2344431T3/es not_active Expired - Lifetime
- 1993-11-30 EP EP07022356A patent/EP1942189B1/en not_active Expired - Lifetime
- 1993-11-30 AT AT07022356T patent/ATE464386T1/de active
- 1993-11-30 WO PCT/US1993/011539 patent/WO1994012628A1/en active IP Right Grant
- 1993-11-30 CA CA2150555A patent/CA2150555C/en not_active Expired - Lifetime
- 1993-11-30 DK DK10157183.4T patent/DK2210947T3/da active
- 1993-11-30 EP EP10157183.4A patent/EP2210947B1/en not_active Expired - Lifetime
- 1993-11-30 PT PT07022356T patent/PT1942189E/pt unknown
- 1993-11-30 PT PT94902448T patent/PT670896E/pt unknown
-
1994
- 1994-06-17 US US08/261,577 patent/US5580757A/en not_active Expired - Lifetime
-
2003
- 2003-12-01 JP JP2003401467A patent/JP3598302B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-24 LU LU91703C patent/LU91703I2/fr unknown
- 2010-06-24 LU LU91704C patent/LU91704I2/fr unknown
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009060918A (ja) * | 1996-09-13 | 2009-03-26 | Transkaryotic Therapies Inc | α−ガラクトシダーゼA欠損症の治療 |
JP2009102321A (ja) * | 1996-09-13 | 2009-05-14 | Transkaryotic Therapies Inc | α−ガラクトシダーゼA欠損症の治療 |
JP2012019793A (ja) * | 1996-09-13 | 2012-02-02 | Shire Human Genetic Therapies Inc | α−ガラクトシダーゼA欠損症の治療 |
US7122354B2 (en) | 1996-09-13 | 2006-10-17 | Transkaryotic Therapies, Inc. | Nucleic acid encoding a chimeric polypeptide |
JP2015044830A (ja) * | 1996-09-13 | 2015-03-12 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼA欠損症の治療 |
JP2015091834A (ja) * | 1999-03-11 | 2015-05-14 | シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼA欠乏症の治療 |
JP2011037867A (ja) * | 1999-03-11 | 2011-02-24 | Transkaryotic Therapies Inc | α−ガラクトシダーゼA欠乏症の治療 |
JP2013241466A (ja) * | 1999-03-11 | 2013-12-05 | Shire Human Genetic Therapies Inc | α−ガラクトシダーゼA欠乏症の治療 |
US7833742B2 (en) | 2002-04-25 | 2010-11-16 | Shire Human Genetic Therapies, Inc. | Treatment of α-galactosidase A deficiency |
US11116823B2 (en) | 2002-04-25 | 2021-09-14 | Takeda Pharmaceutical Company Limited | Treatment of α-galactosidase a deficiency |
US9523113B2 (en) | 2002-04-25 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | Treatment of α-galactosidase A deficiency |
US9267166B2 (en) | 2002-04-25 | 2016-02-23 | Shire Human Genetic Therapies, Inc. | Treatment of α-galactosidase A deficiency |
US8741620B2 (en) | 2003-04-27 | 2014-06-03 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
US9220737B2 (en) | 2003-04-27 | 2015-12-29 | Protalix Ltd. | Plant cell culture expressing human lysosomal proteins and uses thereof |
JP2011184445A (ja) * | 2003-04-27 | 2011-09-22 | Protalix Ltd | 植物培養における高マンノースタンパク質の製造 |
US10364413B2 (en) | 2007-05-07 | 2019-07-30 | Protalix Ltd. | Large scale disposable bioreactor |
JPWO2011108451A1 (ja) * | 2010-03-01 | 2013-06-27 | 日本ケミカルリサーチ株式会社 | 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法 |
JP2013520986A (ja) * | 2010-03-02 | 2013-06-10 | プロタリクス リミテッド | 安定化α−ガラクトシダーゼおよびその使用 |
JP2016530893A (ja) * | 2013-09-16 | 2016-10-06 | ジェンザイム・コーポレーション | 細胞培養物を処理する方法およびシステム |
JP2020124204A (ja) * | 2013-09-16 | 2020-08-20 | ジェンザイム・コーポレーション | 細胞培養物を処理する方法およびシステム |
JP2022050549A (ja) * | 2013-09-16 | 2022-03-30 | ジェンザイム・コーポレーション | 細胞培養物を処理する方法およびシステム |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4005629B2 (ja) | 生物学的に活性なα−ガラクトシダーゼAのクローニング及び発現 | |
US5356804A (en) | Cloning and expression of biologically active human α-galactosidase A | |
US5382524A (en) | Cloning and expression of biologically active α-n-acetylgalactosaminidase | |
US6541254B1 (en) | Glycosylation variants of iduronate 2-sulfatase | |
US5433946A (en) | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases | |
US20050196833A1 (en) | Cyclic GMP-binding, cyclic GMP-specific phosphodiesterase materials and methods | |
US20070238651A1 (en) | Nucleic acids and proteins of a rat ganglioside GM1-specific alpha1-2fucosyltransferase and uses thereof | |
Berg et al. | Purification and characterization of recombinant human lysosomal α-mannosidase | |
Vladutiu | Effect of the co-existence of galactosyl and phosphomannosyl residues on β-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts | |
AU7639294A (en) | Recombinant alpha-galactosidase enzyme and cdna encoding said enzyme | |
Bielicki et al. | Recombinant canine α-L-fucosidase: expression, purification, and characterization | |
Von Figura | Acid hydrolase production, release and uptake by cultured fibroblasts | |
Douglas | Studies on N-acetal-beta-D-hexosaminidases in human placenta | |
Gafuik | The role of mouse and human lysosomal sialidase in the catabolism of ganglioside G [subscript] M₂ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060817 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061002 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070620 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070824 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100831 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110831 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110831 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120831 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120831 Year of fee payment: 5 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120831 Year of fee payment: 5 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120831 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130831 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |